Akèy › Kansè Selil Plazmatik
Etid klinik pou Kansè Selil Plazmatik ap rekrite nan Etazini
24 etid pou Kansè Selil Plazmatik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX5 etid
- Boston, MA5 etid
- New York City, NY4 etid
- Atlanta, GA4 etid
- Miami, FL3 etid
- Durham, NC3 etid
Pa eta
- Florid4 etid
- Georgia4 etid
- Kalifòni3 etid
- Massachusetts5 etid
- New Jersey4 etid
- New York6 etid
- North Carolina4 etid
- Texas7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Rutgers University Study of the Genetics of Blood Cancers
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 110 · Tout sèks · Mizajou Sep 25, 2026 · NCT07714044Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04879043Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 7 a 80 · Tout sèks · Mizajou Sep 1, 2026 · NCT00106925MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Aug 20, 2026 · NCT06066359A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07426484Delayed Toxicities Post-CAR-T
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT07665307Pre-malignant States to Hematologic Malignancies in Firefighters
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 49 · Tout sèks · Mizajou Jul 13, 2026 · NCT06870760Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05055063High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Ap rekriteFaz 1
Laj 18 a 100 · Tout sèks · Mizajou Jun 4, 2026 · NCT06313502A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou May 26, 2026 · NCT07052916Pilot Imaging Study of Leukemia
Ap rekriteFaz 1
Laj 4 a 80 · Tout sèks · Mizajou Apr 23, 2026 · NCT03633955Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT05336383Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT05745285Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Ap rekrite
Laj 21 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT07390071Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Dec 11, 2025 · NCT06518551Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 3, 2025 · NCT06947083Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT07075510Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643HEME Home Transfusion Program
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2025 · NCT06487247Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 10, 2025 · NCT05597345A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 2, 2024 · NCT06271252Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.